Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study
Che-Chia Hsu, Yu-Huei Huang, Tsen-Fang Tsai · 2026
Read Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study by Che-Chia Hsu, Yu-Huei Huang, Tsen-Fang Tsai (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13280268.txt.
Description
Che-Chia Hsu and colleagues published a 2026 retrospective study asking whether longer biologic treatment buys longer remission after the drug stops in moderate-to-severe psoriasis. In Taiwan, reimbursement capped biologics near two and a half years, while pivotal trials treated patients for at least four. The two-center study compared 113 shorter-course patients with 51 longer-course patients on three biologics. It tracked time until relapse after discontinuation.
Median drug-free remission lasted 211 days after long treatment against 111 days after short treatment. The advantage concentrated in the interleukin-23 blockers: long-course risankizumab cut relapse risk by about two thirds in adjusted analysis, and guselkumab leaned the same way without reaching significance. The interleukin-17 blocker secukinumab showed no difference. The authors read the pattern as a disease-modifying effect of sustained interleukin-23 inhibition. They label the findings preliminary, needing larger prospective confirmation before reimbursement policy leans on them.
Catalog record
| CREATOR | Che-Chia Hsu, Yu-Huei Huang, Tsen-Fang Tsai |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |